How I treat acute myeloid leukemia in the era of new drugs
CD DiNardo, AH Wei - Blood, The Journal of the American …, 2020 - ashpublications.org
The acute myeloid leukemia (AML) treatment landscape has changed substantially since
2017. New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2 …
2017. New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2 …
Clinical use of FLT3 inhibitors in acute myeloid leukemia
G Sutamtewagul, CE Vigil - OncoTargets and therapy, 2018 - Taylor & Francis
Acute myeloid leukemia (AML) is a highly heterogeneous disease. Mutation with internal
tandem duplication of fms-like tyrosine kinase-3 (FLT3-ITD) is one of the two most common …
tandem duplication of fms-like tyrosine kinase-3 (FLT3-ITD) is one of the two most common …
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia
MEM Percival, EH Estey - Cancer, 2019 - Wiley Online Library
Patients with acute myeloid leukemia (AML) who achieve a morphologic complete remission
still can have measurable residual disease (MRD) detected by multiparametric flow …
still can have measurable residual disease (MRD) detected by multiparametric flow …
A method for overcoming plasma protein inhibition of tyrosine kinase inhibitors
DJ Young, B Nguyen, L Li, T Higashimoto, MJ Levis… - Blood cancer …, 2021 - AACR
FMS-like tyrosine kinase 3 (FLT3) is the most frequently mutated gene in acute myeloid
leukemia and a target for tyrosine kinase inhibitors (TKI). FLT3 TKIs have yielded limited …
leukemia and a target for tyrosine kinase inhibitors (TKI). FLT3 TKIs have yielded limited …
Polyclonal heterogeneity: the new norm for secondary clinical resistance to targeted monotherapy in relapsed leukemia?
AH Wei, AW Roberts - Cancer Discovery, 2019 - AACR
In this issue, McMahon and colleagues demonstrate that secondary clinical resistance to the
FLT3 inhibitor gilteritinib in relapsed acute myeloid leukemia is often polyclonal and …
FLT3 inhibitor gilteritinib in relapsed acute myeloid leukemia is often polyclonal and …
Identifying effective drug combinations for patients with acute myeloid leukemia
M Yilmaz, T Kadia, F Ravandi - Expert review of anticancer therapy, 2020 - Taylor & Francis
Introduction The development of high-throughput sequencing technologies and the
relentless pursuit of quality translational and clinical research allowed us to understand the …
relentless pursuit of quality translational and clinical research allowed us to understand the …